S 832 · in committee · significant
EPIC Act of 2025
- healthcare
What this bill does
- This bill extends the market approval requirement for drugs to qualify for Medicare price negotiation from 7 years to 11 years.
- It affects Medicare beneficiaries, pharmaceutical companies, and the Centers for Medicare & Medicaid Services.
- The change takes effect in 2028 and delays when drugs become subject to federal price negotiation.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How might extending the market approval period from 7 to 11 years affect Medicare beneficiaries' access to lower drug prices?
- 02
What trade-offs exist between giving pharmaceutical companies longer periods before price negotiation and reducing Medicare's negotiating power?
- 03
How could this 4-year delay in price negotiations impact federal healthcare spending and drug development incentives?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · R-NC
Thom Tillis
Citizen cosponsors
0
In Congress
7/ 100
Senators cosponsoring
Introduced 2025-03-04
Joining the bill
Legislative timeline
2025-03-04 · senate · IntroReferral
Read twice and referred to the Committee on Finance.
2025-03-04 · IntroReferral
Introduced in Senate
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.